ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
16.09
-0.07 (-0.43%)
At close: Feb 20, 2026, 4:00 PM EST
15.65
-0.44 (-2.72%)
After-hours: Feb 20, 2026, 7:44 PM EST
ProMIS Neurosciences Employees
As of December 31, 2024, ProMIS Neurosciences had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$3,660,408
Market Cap
144.29M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2023 | 7 | 0 | - | 6 | 1 |
| Dec 31, 2022 | 7 | 1 | 16.67% | 6 | 1 |
| Dec 31, 2021 | 6 | 5 | 500.00% | 5 | 1 |
| Dec 31, 2020 | 1 | - | - | 1 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Sangamo Therapeutics | 183 |
| Innate Pharma | 174 |
| ProQR Therapeutics | 166 |
| Adagene | 138 |
| Vaxart | 105 |
| Connect Biopharma Holdings | 62 |
| Elicio Therapeutics | 32 |
| Corbus Pharmaceuticals Holdings | 28 |
PMN News
- 17 days ago - ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 22 days ago - ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Announces Reverse Stock Split - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights - GlobeNewsWire